Qiagen Consolidates, Invests $10M in Maryland Facilities | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today announced changes to its Maryland operations with the consolidation of three facilities into two and a $10 million investment into the businesses.

As part of the changes, Qiagen will shutter its Gaithersburg manufacturing facility and move it to the company's Germantown site, which will manufacture some of Qiagen's highest volume diagnostics assays, including the digene HC2 HPV Test for cervical cancer prevention.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.